共 147 条
- [1] Kim JH(2017)Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis Retina 37 2254-2261
- [2] Chang YS(2008)The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis Ophthalmology 115 116-126
- [3] Kim JW(2014)Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis Lancet Glob Health 2 e106-e116
- [4] Wong TY(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
- [5] Chakravarthy U(2009)Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 57-65.e5
- [6] Klein R(2014)Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Cochrane Database Syst Rev 8 CD005139-2299
- [7] Wong WL(2016)Aflibercept for neovascular age-related macular degeneration Cochrane Database Syst Rev 2 CD011346-201
- [8] Su X(2013)Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 2292-58.e1
- [9] Li X(2014)Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 193-1740
- [10] Rosenfeld PJ(2009)A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 43-150